Clinically, PGC1α is induced in BRAFV600 melanoma patients treated with BRAFi, either alone12 or in combination with MEK inhibitors13, whilst tumours that relapse following MAPK inhibitor treatment display an elevated mitochondrial biogenesis signature14. This evidence concerns the gene PPARGC1A and melanoma.